|
1
|
Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
|
N Engl J Med
|
2009
|
8.20
|
|
2
|
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.
|
Science
|
2002
|
6.46
|
|
3
|
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
|
J Clin Invest
|
2007
|
2.63
|
|
4
|
Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells.
|
J Clin Invest
|
2005
|
1.92
|
|
5
|
Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.
|
Nat Med
|
2002
|
1.80
|
|
6
|
SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells.
|
Blood
|
2005
|
1.44
|
|
7
|
X-linked Opitz syndrome: novel mutations in the MID1 gene and redefinition of the clinical spectrum.
|
Am J Med Genet A
|
2003
|
1.18
|
|
8
|
Innate-like effector differentiation of human invariant NKT cells driven by IL-7.
|
J Immunol
|
2008
|
0.94
|
|
9
|
IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.
|
Mol Ther
|
2004
|
0.82
|
|
10
|
Bone marrow clonogenic capability, cytokine production, and thymic output in patients with common variable immunodeficiency.
|
J Immunol
|
2005
|
0.79
|